Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Patients with newly-diagnosed DLBCL receiving R-CHOP at or near full-dose intensity have improved overall survival, according to study authors.
A study of the use of precision medicine-based "radiomic" features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.
Given the high likelihood of comorbidities and poor performance status in older patients with PCNSL, alternative treatment approaches are needed for this population of patients.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
NICE Recommends Use of Tisagenlecleucel for Adults With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Adults in the UK with R/R DLBCL and their health care providers now have the option of considering treatment with tisagenlecleucel, a CAR-T cell therapy.
Expression Levels of NOTCH3 Minus Exon 16 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma
Spliced events in NOTCH genes may facilitate risk stratification for patients with certain subtypes of DLBCL.
Initiation of a phase 1 clinical trial of ALLO-501, an allogeneic CAR-T candidate, in patients with NHL is planned for early 2019.
Detection of specific mutations in genes encoding for PD-L1 and PD-L2 may help predict which patients with lymphoma will benefit from immune checkpoint inhibitor therapy.
The leading cause of death for patients with follicular lymphoma was the disease itself, despite gains in survival due to rituximab treatment.
In the ZUMA-1 trial, axicabtagene ciloleucel showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma.
Nivolumab monotherapy for R/R DLBCL failed to confer improved objective response rates, but did produce durable responses in 3 individuals.
Patients younger than 65 with double expressor diffuse large B-cell lymphoma had better outcomes with dose-adjusted EPOCH plus rituximab than R-CHOP.
Cellular examination of follicular lymphoma reveals malignant B-cell types, coexpression of T-cell immune checkpoints.
Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.
Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure
US FDA recently approved rituximab biosimilar as monotherapy and in combination with chemotherapy.
Study shows risk of second primary malignancy or transformation to lymphoma is low.
Inferior patient outcomes from treatment with axi-cel were linked to poor performance status and increased tumor bulk in patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies